| Lloyd K Richless, MD | |
|
251 7th St, Suite 201b, New Kensington, PA 15068-6534 | |
| (724) 335-6662 | |
| (724) 335-3010 |
| Full Name | Lloyd K Richless |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 43 Years |
| Location | 251 7th St, New Kensington, Pennsylvania |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609923697 | NPI | - | NPPES |
| 252044 | Other | PA | UPMC |
| 306284 | Other | PA | HEALTH ASSURANCE |
| 461863 | Other | PA | BC BS |
| 466675 | Other | PA | AETNA US HEALTHCARE |
| 1006735 | Other | PA | GATEWAY |
| 1021909 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD 027711E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Acmh Hospital | Kittanning, PA | Hospital |
| Entity Name | Lloyd K Richless Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710376546 PECOS PAC ID: 8820312812 Enrollment ID: O20150122001028 |
News Archive
Phase Forward, a leading provider of data solutions for clinical trials and drug safety, today announced the availability of version 7.2 of its Empirica™ Signal product, a significant new release of the company's flagship signal detection and management software. The Empirica Signal solution is a state-of-the-art data mining and knowledge management tool and a cornerstone component of Phase Forward's Empirica Suite of pharmacovigilance and risk management products.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the "American Recovery and Reinvestment Act of 2009". The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.
Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.
"Poor hospital care poses a risk to the lives of many patients in the developing world," according to a study published in the British Medical Journal (BMJ) on Tuesday, BBC News reports.
Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lloyd K Richless, MD 251 7th St, Suite 201b, New Kensington, PA 15068-6534 Ph: (724) 335-6662 | Lloyd K Richless, MD 251 7th St, Suite 201b, New Kensington, PA 15068-6534 Ph: (724) 335-6662 |
News Archive
Phase Forward, a leading provider of data solutions for clinical trials and drug safety, today announced the availability of version 7.2 of its Empirica™ Signal product, a significant new release of the company's flagship signal detection and management software. The Empirica Signal solution is a state-of-the-art data mining and knowledge management tool and a cornerstone component of Phase Forward's Empirica Suite of pharmacovigilance and risk management products.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the "American Recovery and Reinvestment Act of 2009". The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.
Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.
"Poor hospital care poses a risk to the lives of many patients in the developing world," according to a study published in the British Medical Journal (BMJ) on Tuesday, BBC News reports.
Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.
› Verified 7 days ago
Kelsey Judith Temple, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 301 11th St Bldg Suitec, New Kensington, PA 15068 Phone: 724-334-3640 | |
Jonathan Kyung Ho Han, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 Eleventh St Ste C, New Kensington, PA 15068 Phone: 724-334-3640 Fax: 724-334-3644 | |
Dr. Shannon K Bolon, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 301 11th St, Suite C, New Kensington, PA 15068 Phone: 724-334-3640 Fax: 724-334-3644 | |
Sheldon Loughner, FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 305 7th St, New Kensington, PA 15068 Phone: 724-339-3900 | |
Dr. Mark Heino, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 305 Seventh St, New Kensington, PA 15068 Phone: 724-339-3900 Fax: 724-334-1704 | |
Ma Charmaine Rapadas Batac, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 943 Fourth Ave, New Kensington, PA 15068 Phone: 724-335-3334 Fax: 724-335-2283 |